Combination Of Bispecific Antibodies Enable Targeted TNFRSF Agonism and Effective Antitumor Activity. (PubMed, Mol Ther) - Sep 12, 2026 - "In the syngeneic Tg model, the paired bsAbs maintained robust efficacy while mitigating peripheral inflammation compared to urelumab. Overall, we established a bsAb combination strategy that amplifies HER2-driven 4-1BB+ T-cell activation and provides an applicable framework for targeting other tumor necrosis factor receptor superfamily members."
Journal • Immunology • Oncology • Systemic Inflammatory Response Syndrome • HER-2 • TNFA
|
|
Eric Hatterer; Krzysztof Masternak; Laurence Chatel; Limin Shang; Lise Nouveau; Lucie Diby; Mark S Cragg; Mikael Pittet; Nicolas Fischer; Pauline Malinge; Valéry Moine; Vanessa Buatois; Walter Ferlin
|